Evidence map›Paper›PMID 37422495›Full record

ArticlePediatric research2023

Therapeutic efficacy of intravenous infusion of mesenchymal stem cells in rat perinatal brain injury.

Kojiro Terada, Masanori Sasaki, Hiroshi Nagahama, Yuko Kataoka-Sasaki, Shinichi Oka, Ryo Ukai, Takahiro Yokoyama, Yusuke Iizuka, Takuro Sakai, Shinobu Fukumura and 3 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Pediatric research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07018739 (Efficacy of Using Mesenchymal Stem Cells With Therapeutic Hypothermia in Infants With Perinatal Hypoxic-Ischemic Encephalopathy), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07018739 phase1 / phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy of Using Mesenchymal Stem Cells With Therapeutic Hypothermia in Infants With Perinatal Hypoxic-Ischemic Encephalopathy: A Double Blind, Randomized Controlled Trial

TypeinterventionalSponsorMahidol UniversityRan2026 to 2033Enrolled40ConditionsHypoxic-Ischemic Encephalopathy, Neonatal, Brain Injuries, Hypoxic-IschemicArmsWharton's jelly-derived mesenchymal stem cells, 0.9 % Normal Saline
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Therapeutic Efficacy of Mesenchymal Stem Cells in Modulating Oxidative Stress in Puromycin-Induced Nephropathy.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Kojiro TeradaDepartment of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, 060-8556, Japan.
Masanori SasakiDepartment of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, 060-8556, Japan. msasaki@sapmed.ac.jp.ORCID 0000-0001-7961-9698
Hiroshi NagahamaDepartment of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, 060-8556, Japan.
Yuko Kataoka-SasakiDepartment of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, 060-8556, Japan.
Shinichi OkaDepartment of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, 060-8556, Japan.
Ryo UkaiDepartment of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, 060-8556, Japan.
Takahiro YokoyamaDepartment of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, 060-8556, Japan.
Yusuke IizukaDepartment of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, 060-8556, Japan.
Takuro SakaiDepartment of Perinatal Medicine, Sapporo Medical University School of Medicine, Sapporo, 060-8556, Japan.
Shinobu FukumuraDepartment of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, 060-8556, Japan.
Takeshi TsugawaDepartment of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, 060-8556, Japan.
Jeffery D KocsisDepartment of Neurology, Yale University School of Medicine, New Haven, CT, USA.
Osamu HonmouDepartment of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, 060-8556, Japan.
Sapporo Medical University · JPYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPerinatal brain injury is multifactorial and primarily associated with brain prematurity, inflammation, and hypoxia-ischemia. Although recent advances in perinatal medicine have improved the survival rates of preterm infants, neurodevelopmental disorders remain a significant complication. We tested whether the intravenous infusion of mesenchymal stem cells (MSCs) had therapeutic efficacy against perinatal brain injury in rats.

methodsPregnant rats at embryonic day (E) 18 received lipopolysaccharide and the pups were born at E21. On postnatal day (PND) 7, the left common carotid artery of each pup was ligated, and they were exposed to 8% oxygen for 2 h. They were randomized on PND10, and MSCs or vehicle were intravenously infused. We performed behavioral assessments, measured brain volume using MRI, and performed histological analyses on PND49.

resultsInfused MSCs showed functional improvements in our model. In vivo MRI revealed that MSC infusion increased non-ischemic brain volume compared to the vehicle group. Histological analyses showed that cortical thickness, the number of NeuN

conclusionsInfused MSCs improve sensorimotor and cognitive functions in perinatal brain injury and enhance neuronal growth. IMPACT: Intravenous infusion of MSCs improved neurological function in rats with perinatal brain injury, including motor, sensorimotor, cognitive, spatial, and learning memory. Infused MSCs increased residual (non-ischemic) tissue volume, number of neuronal cells, GABAergic cells, and cortical synapses in the contralesional (right) hemisphere. Intravenous administration of MSC might be suitable for the treatment of perinatal brain injury.

Indexed as

Brain InjuriesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsDisease Models, AnimalHumansInfant, NewbornInfant, PrematureInfusions, IntravenousRatsRats, Sprague-Dawley

Identifiers

PMID37422495
OpenAlexW4383621207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.